Houston-based Alaunos (NASDAQ:TCRT), which changed its name from Ziopharm Oncology on January 26, is a small (~$200 million market cap) clinical-stage company focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer technology and its TCR library targeting tumor-specific oncogenic gene mutations called neoantigens. The TCR-T Library Phase 1/2 trial (TCR001-201) is an open label, dose escalation study being conducted by the renowned University of Texas MD Anderson Cancer Center. The next patient is anticipated to be treated sometime this quarter.